Patient Groups Recommend Overhaul For Failing EU Compassionate Use Programs
Executive Summary
An alliance of patient organizations for rare diseases says most EU member states are not doing enough to help patients with life-threatening diseases get timely access to innovative drugs on compassionate grounds. A time difference of more than three years may exist between patients benefiting from a compassionate use treatment, depending on where they live.